Ripretinib is Deciphera's (DCPH) lead drug candidate and it is being tested in GIST, or gastrointestinal stromal tumors. Recently, the drug fared positively in a phase 3 trial called INVICTUS evaluating ripretinib in patients with fourth-line and fourth-line plus GIST.
Given those results, it is becoming important to be able to put a number to the drug's market potential, and the company's eventual valuation.
However, it is something of a problem to determine ripretinib's market potential because, as we said in our previous article, it isn't just GIST that the drug is targeting.